Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor.
Targeted transgene addition can provide persistent gene expression while circumventing the gene silencing and insertional mutagenesis caused by viral vector mediated random integration. This protocol describes a universal and efficient transgene targeted addition platform in human iPSCs based on utilization of validated open-source TALENs and a gene-trap-like donor to deliver transgenes into a safe harbor locus. Importantly, effective gene editing is rate-limited by the delivery efficiency of gene editing vectors. Therefore, this protocol first focuses on preparation of iPSCs for transfection to achieve high nuclear delivery efficiency. When iPSCs are dissociated into single cells using a gentle-cell dissociation reagent and transfected using an optimized program, >50% cells can be induced to take up the large gene editing vectors. Because the AAVS1 locus is located in the intron of an active gene (PPP1R12C), a splicing acceptor (SA)-linked puromycin resistant gene (PAC) was used to select targeted iPSCs while excluding random integration-only and untransfected cells. This strategy greatly increases the chance of obtaining targeted clones, and can be used in other active gene targeting experiments as well. Two weeks after puromycin selection at the dose adjusted for the specific iPSC line, clones are ready to be picked by manual dissection of large, isolated colonies into smaller pieces that are transferred to fresh medium in a smaller well for further expansion and genetic and functional screening. One can follow this protocol to readily obtain multiple GFP reporter iPSC lines that are useful for in vivo and in vitro imaging and cell isolation.
National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health.
Trevor
T
Cerbini
National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health.
Yongquan
Y
Luo
Q Therapeutics.
Mahendra S
MS
Rao
National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health; jizhong.zou@nih.gov.
Jizhong
J
Zou
D018274:Electroporation / Q000379:methods; D015870:Gene Expression; D018390:Gene Targeting / Q000379:methods; D005818:Genetic Engineering / Q000379:methods*; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins / Q000235:genetics; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000502:physiology*; D054645:Protein Phosphatase 1 / Q000235:genetics; D011691:Puromycin / Q000494:pharmacology; D014162:Transfection / Q000379:methods*; D019076:Transgenes
D049452:Green Fluorescent Proteins; D011691:Puromycin; C540874:PPP1R12C protein, human; D054645:Protein Phosphatase 1